Drug Profile
Research programme: integrin alpha-9 antagonists - Kidswell Bio/Kaken
Alternative Names: GND-001Latest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Gene Techno Science
- Developer Kaken Pharmaceutical; Kidswell Bio
- Class Antibodies; Antineoplastics
- Mechanism of Action Integrin alpha9 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Bone disorders; Cancer; Immunological disorders
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Immunological-disorders in Japan (Parenteral)
- 01 Jul 2021 Gene Techno Science is now called Kidswell Bio
- 28 May 2021 No recent reports of development identified for preclinical development in Cancer in Japan (Parenteral)